Wikipedia:Articles for deletion/Divi's Laboratories

{{AFD help}}

:{{la|Divi's Laboratories}} – (View AfDView log)

:({{Find sources AFD|title=Divi's Laboratories}})

Promotional article about a company mostly sourced to primary sources and does not seem to meet WP:NCORP, WP:GNG. Sources cited are self-published websites, listings in company's directory, routine announcements with no wide coverage. Although It is a public listed company, I could not locate in-depth coverage in secondary, reliable sources. It was previously CSDed and deleted for advertising issues[https://en.wikipedia.org/wiki/Special:Log?type=delete&user=&page=Divi%27s_Laboratories&wpdate=&tagfilter=&subtype=]Umakant Bhalerao (talk) 10:55, 18 October 2020 (UTC)

:Note: This discussion has been included in the list of Companies-related deletion discussions. Umakant Bhalerao (talk) 10:55, 18 October 2020 (UTC)

:Note: This discussion has been included in the list of India-related deletion discussions. Shellwood (talk) 11:01, 18 October 2020 (UTC)

:*Keep: I don't see how this article is promotional at all. There are plenty of independent secondary sources that cover this company in detail: [https://economictimes.indiatimes.com/markets/stocks/news/what-makes-the-latest-pharma-company-to-enter-nifty-very-different-from-its-peers-in-the-index/articleshow/77791892.cms][https://www.cnbctv18.com/healthcare/why-the-street-is-positive-on-divis-labs-905171.htm][https://www.business-standard.com/article/companies/choke-in-api-supplies-from-china-creates-huge-opportunity-for-divi-s-labs-120022501212_1.html][https://www.business-standard.com/article/companies/expansions-clean-track-record-helping-divi-s-labs-tap-new-opportunities-119121001259_1.html][https://www.business-standard.com/article/companies/divis-labs-earmarks-rs-15-bn-for-capex-as-greefield-kakinada-project-stalls-118102900614_1.html][https://www.bloombergquint.com/bq-blue-exclusive/not-just-bulk-drugs-this-segment-too-is-doing-well-for-divis-laboratories][https://economictimes.indiatimes.com/markets/stocks/news/was-june-quarter-show-a-one-time-surprise-from-divis-lab/articleshow/77498413.cms][https://www.bloombergquint.com/business/divis-labs-vying-for-no-2-spot-among-indias-generics-dominated-pharma-stocks][https://www.moneycontrol.com/news/business/divis-laboratories-begins-commercial-production-at-visakhapatnam-unit-5015951.html][https://www.thehindu.com/business/divis-labs-develops-process-to-make-covid-19-drugs-from-indigenous-inputs/article32603822.ece][https://www.business-standard.com/article/markets/divis-lab-hits-new-high-as-andhra-pradesh-unit-get-zero-483-observations-120020100272_1.html][https://www.bloombergquint.com/research-reports/motilal-oswal-divis-labs-on-a-strong-growth-trajectory][https://www.business-standard.com/article/news-cm/divis-laboratories-ltd-stays-supported-120080400614_1.html][https://www.business-standard.com/article/news-cm/divis-laboratories-ltd-extends-gains-120100800562_1.html]

::Of the 15 references in the article's reflist, I count 11 that are independent, secondary sources so you'll have to expound on your claim that most sources are primary.

::AfD's should be a last resort, I see this as a hasty attempt to delete an article that clearly needs some work but is undeniably notable. The page was last deleted in 2008, 12 years ago. Since then the company has grown to become one of the [https://www.businesstoday.in/magazine/features/indian-bulk-drug-makers-becoming-world-leaders-niche-areas/story/210082.html largest] API manufacturers in India and has also been included in the NIFTY 50 index. Therefore, I vehemently oppose. Prolix 💬 13:04, 18 October 2020 (UTC)

:::{{re|Prolix}} It was not a knee jerk decision at all. In fact i checked all sources carefully and did a BEFORE search too before opening this AfD and as stated above the article is filled with primary sources and the secondary sources that are there are either announcements or speak about company's growth in terms of its deal with companies, revenues, funding...etc. I was aware of the sources you pointed to, they are also more or less the same. Some of them seem to me PR pieces and do not amount to establishing notability. {{ping|HighKing}}, {{ping|Premeditated Chaos}}, {{ping|SamHolt6}} are a dab hand at identifying sources.--Umakant Bhalerao (talk) 08:21, 20 October 2020 (UTC)

::::{{u|Umakant Bhalerao}}, I am aware of the problems with the article, there are various maintenance templates dedicated to the issues you point out which could have been used instead of starting an AfD. You really need to elaborate on how the sources I linked to are {{tq|'more or less the same'}} and {{tq|'PR pieces'}}. A few of the sources are analysis articles from reputable sources while others are dedicated articles about the company's expansion projects, all of which clearly pass WP:SIRS. You're seriously claiming that articles such as [https://economictimes.indiatimes.com/markets/stocks/news/was-june-quarter-show-a-one-time-surprise-from-divis-lab/articleshow/77498413.cms this], [https://www.cnbctv18.com/healthcare/why-the-street-is-positive-on-divis-labs-905171.htm this], and [https://www.thehindu.com/business/divis-labs-develops-process-to-make-covid-19-drugs-from-indigenous-inputs/article32603822.ece this], which are entirely about this company, published by sources such as The Economic Times, The Hindu and CNBC, which are considered secondary, independent, and reliable sources do not qualify as significant enough coverage? Prolix 💬 10:31, 20 October 2020 (UTC)

• Keep. It is a component of the NIFTY 50. Major company for which WP:LISTED (although it is not a policy or guideline) is relevant. Like Prolix, I don't see the WP:PROMO issues here; the promotional content, such as there is, can be fixed. AleatoryPonderings (talk) 13:42, 18 October 2020 (UTC)
• Keep as the issues can be fixed. The company is notable now and also the part of NIFTY 50 as pointed by {{np|AleatoryPonderings}}. Also, the article was CSD long back in 2008, and more than a decade has passes and it has gained notability during the course of time. ~ Amkgp 💬 20:32, 22 October 2020 (UTC)
• Speedy Keep: Being part of NIFTY 50 itself is more than enough to justify notability. With a market cap of around 12 billion USD, its among the top 100 listed companies of India and currently the second biggest Indian pharma company. (India is the largest producer of generic medicine in the world) Roller26 (talk) 06:22, 23 October 2020 (UTC)
• Keep Notable within its sector as one of the top companies in its field (API manufacturing). Not overly promotional and mentions basic facts, and meets WP:SIGCOV. Ambrosiawater (talk) 05:41, 24 October 2020 (UTC)

{{clear}}

:The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.